



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy

Søgaard, Mette; Skjøth, Flemming; Nielsen, Peter B.; Smit, Jesper; Dalager-Pedersen, Michael; Larsen, Torben B.; Lip, Gregory Y. H.

Published in:
JAMA NETWORK OPEN

DOI (link to publication from Publisher):
[10.1001/jamanetworkopen.2022.13945](https://doi.org/10.1001/jamanetworkopen.2022.13945)

Creative Commons License
CC BY 4.0

Publication date:
2022

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Søgaard, M., Skjøth, F., Nielsen, P. B., Smit, J., Dalager-Pedersen, M., Larsen, T. B., & Lip, G. Y. H. (2022). Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. *JAMA NETWORK OPEN*, 5(5), E2213945. Article e2213945. <https://doi.org/10.1001/jamanetworkopen.2022.13945>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy

Mette Søgaard, DVM, PhD; Flemming Skjøth, MSc, PhD; Peter B. Nielsen, MPH, PhD; Jesper Smit, MD, PhD; Michael Dalager-Pedersen, MD, PhD; Torben B. Larsen, MD, PhD; Gregory Y. H. Lip, MD, PhD

Abstract

IMPORTANCE New-onset atrial fibrillation (AF) is commonly reported in patients with severe infections. However, the absolute risk of thromboembolic events without anticoagulation remains unknown.

OBJECTIVE To investigate the thromboembolic risks associated with AF in patients with pneumonia, assess the risk of recurrent AF, and examine the association of initiation of anticoagulation therapy with new-onset AF.

DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study used linked Danish nationwide registries. Participants included patients hospitalized with incident community-acquired pneumonia in Denmark from 1998 to 2018. Statistical analysis was performed from August 15, 2021, to March 12, 2022.

EXPOSURES New-onset AF.

MAIN OUTCOMES AND MEASURES Thromboembolic events, recurrent AF, and all-cause death. Estimated risks were calculated for thromboembolism without anticoagulation therapy, new hospital or outpatient clinic contact with AF, initiation of anticoagulation therapy, and all-cause death at 1 and 3 years of follow-up. Death was treated as a competing risk, and inverse probability of censoring weights was used to account for patient censoring if they initiated anticoagulation therapy conditioned on AF.

RESULTS Among 274 196 patients hospitalized for community-acquired pneumonia, 6553 patients (mean age [SD], 79.1 [11.0] years; 3405 women [52.0%]) developed new-onset AF. The 1-year risk of thromboembolism was 0.8% (95% CI, 0.8%-0.8%) in patients without AF vs 2.1% (95% CI, 1.8%-2.5%) in patients with new-onset AF without anticoagulation; this risk was 1.4% (95% CI, 1.0%-2.0%) among patients with AF with intermediate stroke risk and 2.8% (95% CI, 2.3%-3.4%) in patients with AF with high stroke risk. Three-year risks were 3.5% (95% CI, 2.8%-4.3%) among patients with intermediate stroke risk and 5.3% (95% CI, 4.4%-6.5%) among patients with high stroke risk. Among patients with new-onset AF, 32.9% (95% CI, 31.8%-34.1%) had a new hospital contact with AF, and 14.0% (95% CI, 13.2%-14.9%) initiated anticoagulation therapy during the 3 years after incident AF diagnosis. At 3 years, the all-cause mortality rate was 25.7% (95% CI, 25.6%-25.9%) in patients with pneumonia without AF vs 49.8% (95% CI, 48.6%-51.1%) in patients with new-onset AF.

CONCLUSIONS AND RELEVANCE This cohort study found that new-onset AF after community-acquired pneumonia was associated with an increased risk of thromboembolism, which may warrant anticoagulation therapy. Approximately one-third of patients had a new hospital or outpatient clinic

(continued)

Key Points

Question What is the risk of thromboembolism and recurrent atrial fibrillation after infection-related atrial fibrillation?

Findings In this cohort study including 274 196 patients with pneumonia, of whom 6553 developed atrial fibrillation, the 1-year risk of thromboembolism was 0.8% in patients without atrial fibrillation vs 2.1% in patients with atrial fibrillation. Among patients with new-onset atrial fibrillation, 32.9% had a recurrent hospital contact with atrial fibrillation and 14.0% initiated anticoagulation therapy during 3-year follow-up.

Meaning These findings suggest that the concept of infection-related atrial fibrillation as a transient condition needs reconsideration given the high risks of recurrence combined with risks of thromboembolism that may warrant anticoagulation therapy.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

contact for AF during the 3-year follow-up, suggesting that AF triggered by acute infections is not a transient, self-terminating condition that reverses with resolution of the infection.

JAMA Network Open. 2022;5(5):e2213945. doi:10.1001/jamanetworkopen.2022.13945

Introduction

Pneumonia and atrial fibrillation (AF) are leading causes of morbidity and mortality worldwide.¹⁻³ Pneumonia is the most common medical diagnosis responsible for hospitalizations in the US.⁴ AF is the most common cardiac arrhythmia and carries up to a 5-fold increased risk of stroke.^{5,6} Pneumonia and AF often coexist, and new-onset AF is a common complication occurring in 4.7% to 9.5% of patients with pneumonia.⁷⁻⁹

A prevailing thought has been that AF triggered by acute infection is a transient and self-terminating condition that reverses with resolution of infection. However, mounting evidence suggest that AF frequently recurs, carrying an increased risk of stroke.¹⁰⁻¹³ Stroke risk in patients with infections and AF has been shown to exceed the risk of both the general population with AF¹⁰⁻¹² and patients with infections without AF.¹³ Nonetheless, guidelines do not provide clear recommendations regarding the role of oral anticoagulant (OAC) therapy to mitigate stroke risk in this context. The decision to initiate OAC therapy should be based on the expected net clinical benefit of OAC therapy, which tracks closely with the absolute risk of stroke and bleeding in patients not receiving OAC therapy. Patients at low stroke risk may have little to no or negative net clinical benefit from therapy. Decision analyses have indicated that the threshold at which OAC treatment yields a net clinical benefit is a stroke risk between 1% to 2% per year.¹⁴⁻¹⁶ However, there is a paucity of data on the absolute thromboembolic risk associated with AF triggered by infections to guide the treatment decision among patients with pneumonia and incident AF.

This nationwide cohort study in Denmark sought to investigate the risks of arterial thromboembolism in patients with new-onset AF after community-acquired pneumonia without anticoagulation therapy. In secondary analyses, we sought to clarify the concept of postinfection new-onset AF as a transient condition by estimating risks of recurrent hospital or outpatient clinic contact with AF, OAC therapy initiation, and all-cause mortality.

Methods

This cohort study included all patients hospitalized with community-acquired pneumonia in Denmark from January 1998 through June 2018. The study was approved by the Danish Data Protection Agency. Registry studies do not require ethical approval or informed consent in Denmark. The data were provided by the Danish Health Data Authority. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.¹⁷

Setting and Data Sources

The source population included the entire population of Denmark (5.6 million inhabitants). Denmark has a tax-funded universal health care system, with equal access to hospitals and primary care for all residents and partial reimbursement of medication costs. A unique civil registration number, assigned to all residents, is used to track individual health services in nationwide registries. This study was based on linkage between 3 registries: (1) the Danish National Patient Register, which includes information on all discharge diagnoses from Danish hospitals¹⁸; (2) The Civil Registration system containing information about age, sex, and vital status¹⁹; and (3) The Danish National Prescription Registry storing information about all claimed prescriptions from Danish people.²⁰

Study Population

We focused on pneumonia because it is a well-characterized prevalent infection that has been consistently linked with cardiovascular disease, including AF.^{21,22} We used the National Patient Register to identify all patients aged at least 18 years at incident primary inpatient pneumonia diagnosis. To exclude confounding from underlying conditions and procedures, we restricted the study to patients with community-acquired pneumonia. Accordingly, we excluded all patients with hospital contact (inpatient or ambulatory) within the 30 days before pneumonia admission. To ensure lookback time for prevalent AF diagnoses, we further excluded patients not residing in Denmark for at least 2 years before pneumonia diagnosis at hospital discharge (index date).

Because we focused on new-onset AF following pneumonia, we screened the pneumonia cohort for status of AF according to diagnoses and prescriptions. We excluded patients with prior AF diagnoses and patients with prior experience of any OAC treatment within 180 days before index date. To investigate risk of outcomes in patients not receiving OAC, we further excluded patients who developed a study end point, initiated OAC treatment, or died during the landmark period of 30 days after discharge from pneumonia hospitalization (eFigure in the [Supplement](#)).

Outcomes and Comorbidity

We studied the at-risk population of patients who were alive and not receiving anticoagulation therapy at the landmark time point of 30 days after the index date and categorized patients according to whether they received a diagnosis of new-onset AF during the landmark period. Follow-up started at the end of the 30-day landmark for a maximum of 3 years, with administrative censoring at December 31, 2018, or at emigration. The primary outcome was a record of arterial thromboembolic event defined as ischemic stroke and/or systemic arterial embolism. Given the severity of the diagnosis of thromboembolism, we only considered events where thromboembolism was the reason for hospital admission; hence, we did not consider secondary and outpatient diagnoses. Validation studies of diagnoses in the National Patient Registry have shown high positive predictive values for AF (approximately 95%), ischemic stroke (approximately 97%),¹⁸ and other cardiovascular diagnoses²³ and comorbidities.¹⁸ Secondary outcomes included recurrent hospital or outpatient clinic contact with AF, OAC therapy initiation, and all-cause mortality. For code definitions, see eTable 1 in the [Supplement](#).

We combined covariate information into the CHA₂DS₂-VAsC (congestive heart failure or left ventricular ejection fraction $\leq 40\%$; hypertension; age ≥ 75 years; diabetes; stroke, transient ischemic attack, or thromboembolism history; vascular disease; age 65-74 years; and female sex) score²⁴ as a measure of stroke risk and a HAS-BLED (hypertension, abnormal kidney or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [age ≥ 65 years], and drugs or alcohol concomitantly) score²⁵ as a measure of bleeding risk (see score definitions in eTable 2 in the [Supplement](#)). Baseline stroke risk according to CHA₂DS₂-VAsC score was categorized on the basis of assigned points: low risk (0, no risk factors when disregarding female sex as a lone risk factor), intermediate risk (1-2 risk factors), and high risk (≥ 3 risk factors) where points for female sex were not considered.

Statistical Analysis

Baseline characteristics at pneumonia diagnosis were summarized using means and SDs for continuous measures and percentages for categorical measures. We used time-to-event analyses to analyze outcome risks measuring time at risk from the 30-day landmark to outcome of interest, emigration, death, or end of follow-up, whichever came first. We investigated the absolute risk of events, taking into account the competing risk of death, and hereby incorporating the diminishing at-risk population under the expectation of a relatively high risk of death and number of outcomes.²⁶ Specifically, we used the Aalen-Johansen estimator to estimate risk development for all end points over time, assuming death as competing risk.²⁴ Cause-specific Cox regression with adjustment for

inclusion period, sex, and age (included as restricted cubic spline) was used to assess the risk of arterial thromboembolism comparing patients with new-onset AF vs those without new-onset AF.

For analyses of arterial thromboembolism in patients with new-onset AF, we censored patients when they started OAC therapy to estimate risks had these patients not initiated anticoagulation and to avoid potential structural selection bias between groups (ie, those at higher risk would be more likely to initiate OAC treatment). We used an inverse probability of censoring weighted (IPCW) analysis to handle informative censoring related to OAC therapy initiation.²⁷ Risk of OAC therapy initiation during follow-up was estimated using a Fine-Grey regression model with death as competing risk and accounting for baseline and time-varying confounding factors, including age, sex, heart failure, hypertension, stroke, diabetes, vascular disease, use of diuretics, renin-angiotensin system inhibitors, β -blocker, or calcium-channel blocker. Recurrent hospital or outpatient clinic contact with AF during follow-up was also included as a time-varying covariate as it may trigger OAC therapy initiation. To allow for time-varying covariates, the data set was structured in the counting process style with multiple rows of data per patient by splitting the follow-up into 7-day periods and evaluate covariates and outcomes at every interval. The IPCW given by the inverse of the survival function of the Fine-Grey model for the outcome of OAC initiation was subsequently estimated by a weighted Cox proportional hazards model.²⁸ To account for repeated observations, we applied a sandwich estimator of the covariance matrix. To reduce influence of extreme IPCWs, the weights were stabilized by the conditional probability of treatment initiation only, given that the inclusion period accounted for the competing risk of death. The 95% CIs for arterial thromboembolic risk were estimated by bootstrapping with 1000 samples. Because of small sample size and few events, we decided post hoc not to use IPCW methods for patients with low stroke risk, because this may reduce the fit of the censoring model and precision of estimated weights. IPCW methods were not used for assessment of secondary outcomes, because patients were not censored according to OAC therapy use.

In sensitivity analyses, we examined potential outcomes of changing guidelines for OAC treatment. First, we stratified the baseline hazard function by inclusion period (1998-2003, 2004-2008, 2009-2013, and 2014-2018) and included interactions between inclusion period and all covariates when estimating IPCW weights. Next, we examined outcome risks with restriction to the most recent period, 2014 to 2018. Finally, although aspirin does not provide optimal stroke protection in patients with AF, there is evidence of some benefit in terms of lower stroke rates compared with no treatment.²⁹ Therefore, we conducted a sensitivity analysis excluding patients with baseline aspirin treatment to ascertain whether this would affect thromboembolic risk.

Statistical tests represent 2-sided hypotheses and a 5% level ($P < .05$) was used to evaluate significance. Analyses were performed using Stata/MP statistical software version 16 (StataCorp) and R statistical software version 3.1.1 (The R Project for Statistical Computing). Statistical analysis was performed from August 15, 2021, to March 12, 2022.

Results

Baseline Characteristics

From January 1, 1998, to September 30, 2018, we identified 293 051 adult patients with incident hospitalized community-acquired pneumonia, of whom 11 107 (3.8%) developed new-onset AF (eFigure in the Supplement). After exclusion of patients who died, initiated OAC therapy, or experienced a thromboembolic event, the 30-day landmark population included 274 196 patients, of whom 6553 (mean age [SD], 79.1 [11.0] years; 3405 women [52.0%]) had new-onset AF (eFigure in the Supplement and Table 1). The new-onset AF group was characterized by higher stroke risk and greater prevalence of cardiovascular and noncardiovascular comorbidities compared with patients with pneumonia without AF. Most patients (6162 of 6443 patients [94%]) with new-onset AF had intermediate or high CHA₂DS₂-VASc score.

Table 1. Baseline Characteristics of Patients Not Receiving Anticoagulation Therapy With Incident Community-Acquired Pneumonia According to Development of New-Onset AF

Characteristic	Patients, No. (%)	
	Pneumonia without AF (n = 267 643)	New-onset AF (n = 6553)
Period of study inclusion		
1998-2003	66 167 (24.7)	1984 (30.3)
2004-2008	56 478 (21.1)	1725 (26.3)
2009-2013	62 182 (23.2)	1840 (28.1)
2014-2018	82 816 (30.9)	1004 (15.3)
Hospital stay, median (IQR), d	4.9 (2.3-8.9)	9.0 (5.1-17.0)
Sex		
Female	138 011 (51.6)	3405 (52.0)
Male	129 632 (48.4)	3148 (48.0)
Age, mean (SD), y	63.8 (18.6)	79.1 (11.0)
Comorbidity		
CHA ₂ DS ₂ -VASC score, mean (SD)	2.1 (1.6)	3.2 (1.4)
Stroke risk categories ^a		
Low	96 492 (36.1)	391 (6.0)
Intermediate	97 248 (36.3)	2584 (39.4)
High	73 903 (27.6)	3578 (54.6)
HAS-BLED score, mean (SD)	1.4 (1.2)	2.2 (1.1)
Prior bleeding	26 005 (9.7)	879 (13.4)
Kidney disease	10 033 (3.7)	396 (6.0)
Alcohol-related disease	2419 (0.9)	75 (1.1)
Heart failure	18 984 (7.1)	1364 (20.8)
Diabetes	30 219 (11.3)	837 (12.8)
Vascular disease	24 446 (9.1)	890 (13.6)
Hypertension	68 000 (25.4)	2601 (39.7)
Prior ischemic stroke	21 248 (7.9)	803 (12.3)
Chronic obstructive pulmonary disease	45 767 (17.1)	1417 (21.6)
Cancer	39 556 (14.8)	1174 (17.9)
Ischemic heart disease	37 508 (14.0)	1451 (22.1)
Myocardial infarction	19 170 (7.2)	734 (11.2)
Venous thromboembolism	9297 (3.5)	248 (3.8)
Comedications		
Digoxin	4323 (1.6)	840 (12.8)
Clopidogrel	10 149 (3.8)	253 (3.9)
Aspirin	57 439 (21.5)	2345 (35.8)
Renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers)	57 902 (21.6)	1764 (26.9)
Statins	47 210 (17.6)	1061 (16.2)
Nonsteroidal anti-inflammatory drug	64 862 (24.2)	1456 (22.2)
β-blocker	35 839 (13.4)	1363 (20.8)
Calcium	40 889 (15.3)	1488 (22.7)
Loop diuretics	42 414 (15.8)	1925 (29.4)
Nonloop diuretics	59 292 (22.2)	2204 (33.6)
Proton-pump inhibitors	57 061 (21.3)	1414 (21.6)
Antibiotics within 30 d	91 831 (34.3)	1760 (26.9)

Abbreviations: AF, atrial fibrillation; CHA₂DS₂-VASC, congestive heart failure or left ventricular ejection fraction ≤40%; hypertension; age ≥75 years; diabetes; stroke, transient ischemic attack, or thromboembolism history; vascular disease; age 65-74 years; and female sex; HAS-BLED, hypertension, abnormal kidney or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age ≥65 years), and drugs or alcohol concomitantly.

^a Baseline stroke risk according to CHA₂DS₂-VASC score was categorized according to assigned points: low risk (0, no risk factors when disregarding female sex as a lone risk factor), intermediate risk (1-2 risk factors), and high risk (≥3 risk factors) where points for female sex were taken into account.

Arterial Thromboembolism

During the 3 years of follow-up, rates of thromboembolic events were significantly higher in patients with new-onset AF than in patients without AF (2.21 cases per 100 person-years [95% CI, 1.97-2.49 cases per 100 person-years] vs 0.83 per 100 person-years [95% CI, 0.81-0.86 cases per 100 person-years]); adjusted hazard ratio [HR], 1.49 [95% CI, 1.32-1.69] (Table 2 and Figure). When we stratified patients with new-onset AF by baseline stroke risk, we observed fewer than 5 thromboembolic events in patients at low stroke risk throughout follow-up. During 1 year of follow-up, there were 38 thromboembolic events among patients with new-onset AF and intermediate stroke risk (IPCW weighted rate of 1.88 events per 100 person-years [95% CI, 1.36-2.68 events per 100 person-years]) and 99 events among patients at high risk (weighted rate of 3.87 events per 100 person-years [95% CI, 3.17-4.76 events per 100 person-years]). At 3 years, the weighted incidence rate was 1.75 events per 100 person-years (95% CI, 1.41-2.20 events per 100 person-years) for patients with intermediate stroke risk and 3.07 events per 100 person-years (95% CI, 2.55-3.70 events per 100 person-years) for patients with high stroke risk. The attenuating rate estimate for 3-year vs 1-year follow-up reflect the diminishing at-risk population due to right censoring (ie, end of study, OAC therapy initiation, or death).

Table 2. Number of Events, Crude, and Weighted Rate of Thromboembolic Events in Patients Not Receiving Anticoagulation Therapy According to Presence of New-Onset AF

Strata	1-y Follow-up			3-y Follow-up		
	Events, No.	Rate, events/100 person-years (95% CI)		Events, No.	Rate, events/100 person-years (95% CI)	
		Crude	Weighted ^a		Crude	Weighted ^a
Pneumonia without AF	2059	0.93 (0.89-0.97)	NA	4982	0.83 (0.81-0.86)	NA
Pneumonia with new-onset AF	137 ^b	2.80 (2.37-3.31)	2.82 (2.38-3.37)	272 ^b	2.21 (1.97-2.49)	2.29 (1.99-2.65)
Baseline stroke risk ^c						
Low	<5 ^b	0.30 (0.04-2.14)	NA ^d	<5 ^b	0.31 (0.10-0.97)	NA ^d
Intermediate	38	1.91 (1.39-2.63)	1.88 (1.36-2.68)	89	1.71 (1.39-2.11)	1.75 (1.41-2.20)
High	99	3.80 (3.12-4.63)	3.87 (3.17-4.76)	183	2.92 (2.53-3.38)	3.07 (2.56-3.70)

Abbreviations: AF, atrial fibrillation; NA, not applicable.

^a Patients with new-onset AF were censored when they started anticoagulation therapy and were weighted by the inverse of the probability of being censored.


^b As required by Danish data protection law, percentages and counts were suppressed for observations with fewer than 5 incidents to prevent disclosure of potentially identifiable information. Accordingly, the number of events among patients at low risk is not included in the overall number of events.

^c Among patients with new-onset AF, baseline stroke risk is determined according to CHA₂DS₂-VASc score (congestive heart failure or left ventricular ejection fraction

≤40%; hypertension; age ≥75 years; diabetes; stroke, transient ischemic attack, or thromboembolism history; vascular disease; age 65-74 years; and female sex) categorized by assigned points: low risk (0, no risk factors when disregarding female sex as a lone risk factor), intermediate risk (1-2 risk factors), and high risk (≥3 risk factors) where points for female sex were not taken into account.

^d Because of low sample size and few events (<5 events), weighted rates were not estimated for patients at low baseline risk of stroke (CHA₂DS₂-VASc score of 0 to 1 when disregarding female sex as a lone risk factor).

Figure. Risk of Thromboembolic Events in Patients Not Receiving Anticoagulation Therapy After Community-Acquired Pneumonia According to Development of New-Onset Atrial Fibrillation (AF)



Patients with new-onset AF were censored when they started anticoagulation therapy and death was treated as a competing risk. Patient data were weighted by the inverse probability of censoring.

At 1 year, the risk of thromboembolism was 0.8% (95% CI, 0.8%-0.8%) in patients without AF vs 2.1% (95% CI, 1.8%-2.5%) in patients with new-onset AF not receiving anticoagulation. Among patients with new-onset AF, the risk was 1.4% (95% CI, 1.0%-2.0%) in patients at intermediate stroke risk and 2.8% (95% CI, 2.3%-3.4%) in high-risk patients (Table 3). At 3-year follow-up, corresponding risks were 3.5% (95% CI, 2.8%-4.3%) in patients with intermediate stroke risk and 5.3% (95% CI, 4.4%-6.5%) in patients with high stroke risk (Figure).

Recurrent Hospital or Outpatient Clinic Contact for AF, OAC Therapy Initiation, and Death

Among patients with new-onset AF, 8.7% (95% CI, 8.1%-9.4%) claimed a prescription for OAC therapy during the first year after hospital admission with community-acquired pneumonia, increasing to 14.0% (95% CI, 13.2%-14.9%) at 3 years (Table 4). Concurrently, 6.7% (95% CI, 4.5%-9.4%) to 9.9% (95% CI, 8.7%-11.1%) claimed a prescription for OAC therapy during the first year depending on baseline stroke risk, increasing to 12.5% (95% CI, 11.4%-13.6%) to 16.1% (95% CI, 14.7%-17.6%) at 3 years (Table 4). Mortality rates were 12.1% (95% CI, 12.0%-12.2%) in patients without AF vs 26.3% (95% CI, 25.2%-27.4%) in patients with new-onset AF at 1 year, and 25.7% (95% CI, 25.6%-25.9%) vs 49.8% (95% CI, 48.6%-51.1%) at 3 years.

Table 3. Absolute Risk of Thromboembolism in Patients Not Receiving Anticoagulation Therapy According to Presence of New-Onset AF

Strata	Thromboembolism risk, % (95% CI) ^a	
	1-y Follow-up	3-y Follow-up
Pneumonia without AF	0.8 (0.8-0.8)	2.0 (2.0-2.1)
Pneumonia with new-onset AF	2.1 (1.8-2.5)	4.4 (3.7-5.0)
Baseline stroke risk ^b		
Low	NA ^c	NA ^c
Intermediate	1.4 (1.0-2.0)	3.5 (2.8-4.3)
High	2.8 (2.3-3.4)	5.3 (4.4-6.5)

Abbreviations: AF, atrial fibrillation; NA, not applicable.

^a Death was treated as a competing risk. Patients with new-onset AF were censored if they started anticoagulation therapy and were weighted by the inverse of the probability of being censored.

^b Among patients with new-onset AF, baseline stroke risk was determined according to CHA₂DS₂-VASc score (congestive heart failure or left ventricular ejection fraction ≤40%; hypertension; age ≥75 years; diabetes; stroke, transient ischemic attack, or thromboembolism history; vascular disease; age 65-74 years; and female sex) assigned points: low risk (0-1, no risk factors when disregarding female sex as a lone risk factor), intermediate risk (1-2 risk factors), and high risk (≥3 risk factors) where points for female sex were not taken into account.

^c Because of low sample size and few events (<5 events), inverse probability of censoring methods was not applied for patients at low baseline risk of stroke (CHA₂DS₂-VASc score of 0-1 when disregarding female sex as a lone risk factor).

Table 4. Absolute Risk of AF Rehospitalization, Initiation of Anticoagulation Therapy, and Death in Patients With New-Onset AF After Community-Acquired Pneumonia Not Receiving OAC Therapy

Strata	Risk, % (95% CI)					
	AF rehospitalization		OAC initiation		All-cause death ^a	
	1-y Follow-up	3-y Follow-up	1-y Follow-up	3-y Follow-up	1-y Follow-up	3-y Follow-up
New-onset AF	20.5 (19.6-21.5)	32.9 (31.8-34.1)	8.7 (8.1-9.4)	14.0 (13.2-14.9)	26.3 (25.2-27.4)	49.8 (48.6-51.1)
Baseline stroke risk ^b						
Low	16.2 (12.7-20.0)	27.7 (23.3-32.2)	6.7 (4.5-9.4)	14.5 (11.2-18.2)	10.8 (8.1-14.4)	17.6 (14.2-21.9)
Intermediate	19.9 (18.4-21.5)	31.6 (29.8-33.5)	9.9 (8.7-11.1)	16.1 (14.7-17.6)	22.8 (21.3-24.5)	43.7 (41.8-45.7)
High	21.5 (20.1-22.8)	34.3 (32.8-35.9)	8.1 (7.3-9.1)	12.5 (11.4-13.6)	30.4 (29.0-32.0)	57.7 (56.1-59.4)

Abbreviations: AF, atrial fibrillation; OAC, oral anticoagulation.

^a Death was treated as a competing risk.

^b Among patients with new-onset AF, baseline stroke risk was determined according to CHA₂DS₂-VASc score (congestive heart failure or left ventricular ejection fraction ≤40%; hypertension; age ≥75 years; diabetes; stroke, transient ischemic attack, or

thromboembolism history; vascular disease; age 65-74 years; and female sex) assigned points: low risk (0-1, no risk factors when disregarding female sex as a lone risk factor), intermediate risk (1-2 risk factors), and high risk (≥3 risk factors) where points for female sex were not taken into account.

Sensitivity Analyses

One-year and 3-year risks of thromboembolic events among patients with new-onset AF changed little when accounting for temporal changes by stratifying the baseline hazard function by inclusion period and including interactions between inclusion period and all covariates in the Fine-Grey regression model (eTable 3 in the [Supplement](#)). Restriction to the years 2014 to 2018 slightly attenuated the thromboembolic risk; 1-year risk of thromboembolic events without anticoagulation was 1.3% in patients at intermediate risk of stroke and 2.5% in high-risk patients. When excluding patients with baseline aspirin treatment the risk of thromboembolic events was 2.1% at 1 year and 3.9% at 3 years.

Discussion

Among 293 051 patients with community-acquired pneumonia and no history of AF, 3.8% developed AF after pneumonia hospitalization. Without OAC therapy, new-onset AF was associated with a 2.1% 1-year risk of arterial thromboembolic events (1.4% among patients with intermediate stroke risk and 2.8% among patients at high risk). The 3-year risks were 3.5% and 5.3%, respectively. These estimates exceed the general threshold of 1.7% per year for vitamin K antagonists and 0.9% for the non-vitamin K OACs for obtaining a positive net clinical benefit of stroke prevention¹⁴⁻¹⁶ and are considerably higher than risks observed among patients with pneumonia without AF. Among patients with new-onset AF, 32.9% (95% CI, 31.8%-34.1%) had a new hospital or outpatient clinic contact with AF and 14.0% (95% CI, 13.2%-14.9%) initiated OAC during follow-up.

Comparison With Other Studies

This study expands the evidence suggesting that there is an increased risk of thromboembolism in patients with infection-related AF, and it adds to the notion that new-onset AF should not be regarded as self-limiting and benign. Previous studies have demonstrated similar relative risk of thromboembolism in patients with infection-related AF compared with patients with AF without infection matched by baseline OAC treatment status¹⁰⁻¹² and in patients with infections without AF.¹³ Among patients with infection-related AF, pneumonia was associated with the highest risk of thromboembolic events,^{10,13} but the association has also been demonstrated in patients with sepsis.³⁰ The benefit of OAC therapy was similar between matched patients with infection-related AF and non-infection-related AF; for infection-related AF, the adjusted HR for thromboembolism was 0.75 (95% CI, 0.68-0.83) compared with those without OAC therapy, and for non-infection-related AF the HR was 0.70 (95% CI, 0.63-0.78).¹⁰ Most previous studies have only reported the relative risks, which does not inform about baseline risk and may obscure the magnitude of the association. In many situations, the absolute risk gives a better representation of the clinical situation, also from the patient's point of view.³¹ Our study reporting absolute risks and focusing on a specific infection in patients without OAC, therefore, supports and strengthens the validity of previous findings.

Potential Explanations and Clinical Implications

Several mechanisms explain why infections can trigger AF, including systemic inflammation, electrophysiological disturbances, metabolic imbalances, hypoxia, and dysolemia.³² New-onset AF after pneumonia may identify a subset of patients who have a substrate for thromboembolism regardless of the arrhythmia. A key finding of our study was that the AF episode was not a transient, self-limited event, because approximately one-third of patients had a new hospital AF diagnosis during follow-up. This corroborates previous findings^{13,33} and suggests that restoration of sinus rhythm with resolution of infection may not protect against AF recurrence. In this respect, infection may merely be a stress test that demonstrates the likelihood for future AF. The substantial observed risk of recurrent AF suggests that individuals with new-onset AF in the context of pneumonia may have underlying predisposition to AF. Indeed, patients with AF in our cohort were older and had a high prevalence of comorbidities, both associated with high risk of AF and thromboembolism.

From a clinical point of view, our study has 2 major implications. First, our findings suggest that new-onset AF during pneumonia is a marker of future AF. This implies that vigilance for recurrent AF may be warranted and that attention should be given to each episode of infection-related AF, regardless of its duration, to tailor surveillance in patients developing this complication. Second, our findings suggest that new-onset AF occurring with pneumonia is associated with a risk of thromboembolism that reaches a level where OAC therapy is considered beneficial. The question remains whether these patients should initiate lifelong OAC therapy. Previously, a UK study found that patients with resolved AF remained at higher risk of stroke than patients without AF.³⁴ According to current guidelines, patients with non-infection-related AF receive OAC therapy according to their perceived stroke risk rather than the heart rhythm displayed at a particular time.^{35,36} The updated European Society of Cardiology guidelines³⁵ state that the clinical pattern of AF (ie, first detected, paroxysmal, persistent, longstanding persistent, or permanent) should not condition the indication to thromboprophylaxis. In the era of non-vitamin K OAC therapy, perhaps it is time for infection-related AF to be treated in the same way as non-infection-related AF, with long-term anticoagulation maintained in patients with manifested clinical stroke risk factors. However, the decision to initiate anticoagulation treatment in the setting of severe infections is complex. High bleeding risk due to systemic activation of the inflammatory response and depletion of coagulation factors and platelets may outweigh the benefits of anticoagulation. Most trials investigating different OAC therapies for stroke prophylaxis excluded patients with AF due to reversible conditions,³⁷⁻⁴⁰ and high-quality evidence regarding the role of OAC in patients with infection-related AF is lacking.

Strengths and Limitations

Our study was strengthened by the completeness of data in a nationwide cohort of patients experiencing incident AF after community-acquired pneumonia. The Danish health care system provides equal access to health care services for all residents regardless of socioeconomic and insurance status. In Denmark, OAC therapy can be purchased only through prescription, and all Danish pharmacies register redeemed prescriptions ensuring complete and accurate registration.

Our study also has limitations. New-onset AF was defined by a record of an *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* diagnosis, and we may have missed episodes given the known risk of brief, self-terminated AF episodes that may be undetected or unreported. Therefore, our findings may not generalize to very brief, self-terminating AF episodes. We lacked information on duration and number of AF episodes during admission, and detailed classification of strokes as cardioembolic vs other was not feasible.

Conclusions

Among patients with community-acquired pneumonia, new-onset AF was associated with increased risks of thromboembolism, which may cross the threshold where OAC therapy is considered beneficial. One-third of patients had a new hospital AF diagnosis during follow-up, indicating that the concept of infection-related AF as a transient condition may need reconsideration. These findings may have rhythm monitoring and treatment implications, and improved communication and monitoring of long-term AF risks is warranted.

ARTICLE INFORMATION

Accepted for Publication: April 7, 2022.

Published: May 26, 2022. doi:10.1001/jamanetworkopen.2022.13945

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2022 Søgaard M et al. *JAMA Network Open*.

Corresponding Author: Mette Søgaard, DVM, PhD, Department of Cardiology, Aalborg University Hospital, Sønder Skovvej 15, 9000 Aalborg, Denmark (mette.soegaard@rn.dk).

Author Affiliations: Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark (Søgaard, Nielsen, Larsen); Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark (Søgaard, Skjøth, Nielsen, Larsen, Lip); Unit for Clinical Biostatistics, Aalborg University Hospital, Aalborg, Denmark (Skjøth); Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark (Smit, Dalager-Pedersen); Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (Lip).

Author Contributions: Dr Søgaard and Mr Skjøth had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Søgaard, Skjøth, Smit, Dalager-Pedersen, Lip.

Acquisition, analysis, or interpretation of data: Søgaard, Skjøth, Nielsen, Dalager-Pedersen, Larsen, Lip.

Drafting of the manuscript: Søgaard, Skjøth, Smit, Lip.

Critical revision of the manuscript for important intellectual content: Skjøth, Nielsen, Smit, Dalager-Pedersen, Larsen, Lip.

Statistical analysis: Søgaard, Skjøth.

Obtained funding: Søgaard, Larsen.

Administrative, technical, or material support: Søgaard, Nielsen, Dalager-Pedersen, Larsen.

Supervision: Nielsen, Smit, Dalager-Pedersen, Lip.

Conflict of Interest Disclosures: Dr Søgaard reported receiving personal fees for consulting from Bayer AG outside the submitted work. Dr Skjøth reported receiving personal fees from Bayer outside the submitted work. Dr Nielsen reported receiving personal fees from Boehringer Ingelheim, BMS/Pfizer, Bayer, and Daiichi-Sankyo; and research grants from Bayer and Daiichi-Sankyo outside the submitted work. Dr Larsen reported receiving personal fees from Pfizer, Bristol Meyers Squibb, Bayer AG, and Merck Sharp & Dome during the conduct of the study. Dr Lip reported being a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No other disclosures were reported.

Funding/Support: This study was supported by the Obel Family Foundation.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. DeLago AJ, Essa M, Ghajar A, et al. Incidence and mortality trends of atrial fibrillation/atrial flutter in the United States 1990 to 2017. *Am J Cardiol*. 2021;148:78-83. doi:10.1016/j.amjcard.2021.02.014
2. Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. *Heart*. 2021;107(11):881-887. doi:10.1136/heartjnl-2020-317656
3. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. *Lancet*. 2015;386(9998):1097-1108. doi:10.1016/S0140-6736(15)60733-4
4. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National Hospital Discharge Survey: 2007 summary. *Natl Health Stat Report*. 2010;(29):1-20, 24.
5. Pritchett EL. Management of atrial fibrillation. *N Engl J Med*. 1992;326(19):1264-1271. doi:10.1056/NEJM199205073261906
6. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. the Copenhagen AFASAK study. *Lancet*. 1989;1(8631):175-179. doi:10.1016/S0140-6736(89)91200-2
7. Perry TW, Pugh MJV, Waterer GW, et al. Incidence of cardiovascular events after hospital admission for pneumonia. *Am J Med*. 2011;124(3):244-251. doi:10.1016/j.amjmed.2010.11.014
8. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. *PLoS Med*. 2011;8(6):e1001048. doi:10.1371/journal.pmed.1001048
9. Soto-Gomez N, Anzueto A, Waterer GW, Restrepo MI, Mortensen EM. Pneumonia: an arrhythmogenic disease? *Am J Med*. 2013;126(1):43-48. doi:10.1016/j.amjmed.2012.08.005
10. Gundlund A, Kümler T, Olesen JB, et al. Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection. *Am Heart J*. 2018;204:43-51. doi:10.1016/j.ahj.2018.07.003

11. Gundlund A, Kümmler T, Bonde AN, et al. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant-Danish nationwide cohort study. *BMJ Open*. 2019;9(9):e028468. doi:10.1136/bmjopen-2018-028468
12. Hansen TG, Pottegård A, Brandes A, et al. New-onset atrial fibrillation among patients with infection in the emergency department: a multicenter cohort study of 1-year stroke risk. *Am J Med*. 2020;133(3):352-359.e3. doi:10.1016/j.amjmed.2019.06.048
13. Gundlund A, Olesen JB, Butt JH, et al. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study. *Eur Heart J*. 2020;41(10):1112-1119. doi:10.1093/eurheartj/ehz873
14. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2011;4(1):14-21. doi:10.1161/CIRCOUTCOMES.110.958108
15. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. *Circulation*. 2017;135(3):208-219. doi:10.1161/CIRCULATIONAHA.116.024057
16. Li Y-G, Lip GYH. Stroke prevention in atrial fibrillation: state of the art. *Int J Cardiol*. 2019;287:201-209. doi:10.1016/j.ijcard.2018.09.057
17. Vandembroucke JP, von Elm E, Altman DG, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology*. 2007;18(6):805-835. doi:10.1097/EDE.0b013e3181577511
18. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol*. 2015;7:449-490. doi:10.2147/CLEP.S91125
19. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol*. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
20. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. *Int J Epidemiol*. 2017;46(3):798-798f. doi:10.1093/ije/dyw213
21. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. *Lancet*. 2013;381(9865):496-505. doi:10.1016/S0140-6736(12)61266-5
22. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. *JAMA*. 2015;313(3):264-274. doi:10.1001/jama.2014.18229
23. Sundbøll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. *BMJ Open*. 2016;6(11):e012832. doi:10.1136/bmjopen-2016-012832
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18(6):695-706. doi:10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
25. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134
26. Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. *Neurology*. 2017;89(7):687-696. doi:10.1212/WNL.0000000000004235
27. Sinyavskaya L, Schnitzer M, Renoux C, Guertin JR, Talbot D, Durand M. Evidence of the different associations of prognostic factors with censoring across treatment groups and impact on censoring weight model specification: the example of anticoagulation in atrial fibrillation. *Am J Epidemiol*. 2021;190(12):2671-2679. doi:10.1093/aje/kwab186
28. Lambert PC. The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights. *Stata J*. 2017;17(1):181-207. doi:10.1177/1536867X1701700110
29. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007
30. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. *Chest*. 2014;146(5):1187-1195. doi:10.1378/chest.14-0003
31. Noordzij M, van Diepen M, Caskey FC, Jager KJ. Relative risk versus absolute risk: one cannot be interpreted without the other. *Nephrol Dial Transplant*. 2017;32(suppl 2):ii13-ii18. doi:10.1093/ndt/gfw465

32. Feldman C, Anderson R. Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia. *Pneumonia (Nathan)*. 2016;8(1):11. doi:10.1186/s41479-016-0011-0
33. Lubitz SA, Yin X, Rienstra M, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. *Circulation*. 2015;131(19):1648-1655. doi:10.1161/CIRCULATIONAHA.114.014058
34. Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. *BMJ*. 2018;361:k1717. doi:10.1136/bmj.k1717
35. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
36. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74(1):104-132. doi:10.1016/j.jacc.2019.01.011
37. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
38. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
39. Granger CB, Alexander JH, McMurray JJV, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
40. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907

SUPPLEMENT.

eTable 1. Definitions on Comorbidity and Concomitant Medication According to ICD-10 Codes and ATC-codes

eTable 2. Risk Score Definition

eTable 3. Results of Sensitivity Analyses Among Patients With an Indication for OAC Therapy (i.e., Intermediate or High Baseline Stroke Risk)

eFigure. Flow Diagram of the Cohort Creation Process